Monalizumab, a humanized anti-NKG2A antibody, enhanced NK and CD8+ T-cells activity as well as the efficacy of Cetuximab in a phase II clinical trial with head and neck squamous cell carcinoma patients [57]. This evidence concerns the gene KLRC1 and head and neck squamous cell carcinoma.